Is nitrodihydropyridine-induced photorelaxation of vascular smooth muscle mediated by nitric oxide?

S. K. O'Neill, F. Lovren, D. Bieger, E. E. Knaus, C. R. Triggle

Research output: Contribution to journalArticle

Abstract

The 1,4-dihydropyridine nifedipine is an important cardiovascular drug used for the control of angina, hypertension and other vascular diseases. Dihydropyridine L-type Ca2+ channel activators and antagonists share many common structural and conformational features that allow them to bind to the same 1,4-dihydropyridine receptor. Certain activators and antagonists of the L-type Ca2+ channel can also photosensitive smooth muscle to the relaxant effects of UV light. The mechanism by which dihydropyridines induce photorelaxation has not been elucidated, but may involve degradation to release NO. Streptozotocin (STZ), BAY k 8644 and PN-202-791 were found to release similar amounts of NO upon photostimulation in vitro. However, STZ was a much less potent photorelaxant than were the two dihydropyridine, thus suggesting differing mechanisms of action. Furthermore, for NO release and photorelaxation, structure-activity studies indicate that a nitro group was required at the 3 position in the dihydropyridine ring. The financial support of the Medical Research Council of Canada is gratefully acknowledged.

Original languageEnglish
Pages (from-to)98
Number of pages1
JournalProceedings of the Western Pharmacology Society
Volume39
Publication statusPublished - 1996
Externally publishedYes

Fingerprint

Vascular Smooth Muscle
Nitric Oxide
Streptozocin
Dihydropyridines
Cardiovascular Agents
Financial Support
L-Type Calcium Channels
Drug and Narcotic Control
Nifedipine
Ultraviolet Rays
Vascular Diseases
Canada
Smooth Muscle
Biomedical Research
Hypertension
1,4-dihydropyridine

ASJC Scopus subject areas

  • Pharmacology

Cite this

Is nitrodihydropyridine-induced photorelaxation of vascular smooth muscle mediated by nitric oxide? / O'Neill, S. K.; Lovren, F.; Bieger, D.; Knaus, E. E.; Triggle, C. R.

In: Proceedings of the Western Pharmacology Society, Vol. 39, 1996, p. 98.

Research output: Contribution to journalArticle

@article{3e24fbf5bf8f4795bc2b247a6178fd6c,
title = "Is nitrodihydropyridine-induced photorelaxation of vascular smooth muscle mediated by nitric oxide?",
abstract = "The 1,4-dihydropyridine nifedipine is an important cardiovascular drug used for the control of angina, hypertension and other vascular diseases. Dihydropyridine L-type Ca2+ channel activators and antagonists share many common structural and conformational features that allow them to bind to the same 1,4-dihydropyridine receptor. Certain activators and antagonists of the L-type Ca2+ channel can also photosensitive smooth muscle to the relaxant effects of UV light. The mechanism by which dihydropyridines induce photorelaxation has not been elucidated, but may involve degradation to release NO. Streptozotocin (STZ), BAY k 8644 and PN-202-791 were found to release similar amounts of NO upon photostimulation in vitro. However, STZ was a much less potent photorelaxant than were the two dihydropyridine, thus suggesting differing mechanisms of action. Furthermore, for NO release and photorelaxation, structure-activity studies indicate that a nitro group was required at the 3 position in the dihydropyridine ring. The financial support of the Medical Research Council of Canada is gratefully acknowledged.",
author = "O'Neill, {S. K.} and F. Lovren and D. Bieger and Knaus, {E. E.} and Triggle, {C. R.}",
year = "1996",
language = "English",
volume = "39",
pages = "98",
journal = "Proceedings of the Western Pharmacology Society",
issn = "0083-8969",
publisher = "Western Pharmacology Society",

}

TY - JOUR

T1 - Is nitrodihydropyridine-induced photorelaxation of vascular smooth muscle mediated by nitric oxide?

AU - O'Neill, S. K.

AU - Lovren, F.

AU - Bieger, D.

AU - Knaus, E. E.

AU - Triggle, C. R.

PY - 1996

Y1 - 1996

N2 - The 1,4-dihydropyridine nifedipine is an important cardiovascular drug used for the control of angina, hypertension and other vascular diseases. Dihydropyridine L-type Ca2+ channel activators and antagonists share many common structural and conformational features that allow them to bind to the same 1,4-dihydropyridine receptor. Certain activators and antagonists of the L-type Ca2+ channel can also photosensitive smooth muscle to the relaxant effects of UV light. The mechanism by which dihydropyridines induce photorelaxation has not been elucidated, but may involve degradation to release NO. Streptozotocin (STZ), BAY k 8644 and PN-202-791 were found to release similar amounts of NO upon photostimulation in vitro. However, STZ was a much less potent photorelaxant than were the two dihydropyridine, thus suggesting differing mechanisms of action. Furthermore, for NO release and photorelaxation, structure-activity studies indicate that a nitro group was required at the 3 position in the dihydropyridine ring. The financial support of the Medical Research Council of Canada is gratefully acknowledged.

AB - The 1,4-dihydropyridine nifedipine is an important cardiovascular drug used for the control of angina, hypertension and other vascular diseases. Dihydropyridine L-type Ca2+ channel activators and antagonists share many common structural and conformational features that allow them to bind to the same 1,4-dihydropyridine receptor. Certain activators and antagonists of the L-type Ca2+ channel can also photosensitive smooth muscle to the relaxant effects of UV light. The mechanism by which dihydropyridines induce photorelaxation has not been elucidated, but may involve degradation to release NO. Streptozotocin (STZ), BAY k 8644 and PN-202-791 were found to release similar amounts of NO upon photostimulation in vitro. However, STZ was a much less potent photorelaxant than were the two dihydropyridine, thus suggesting differing mechanisms of action. Furthermore, for NO release and photorelaxation, structure-activity studies indicate that a nitro group was required at the 3 position in the dihydropyridine ring. The financial support of the Medical Research Council of Canada is gratefully acknowledged.

UR - http://www.scopus.com/inward/record.url?scp=33748182433&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748182433&partnerID=8YFLogxK

M3 - Article

VL - 39

SP - 98

JO - Proceedings of the Western Pharmacology Society

JF - Proceedings of the Western Pharmacology Society

SN - 0083-8969

ER -